Epsilon Healthcare Posts Record $3.14M Receipts, Accelerates Growth Trajectory

Record Quarterly Receipts Signal Accelerated Growth

Epsilon Healthcare Limited (ASX:EPN) has shattered its previous revenue records, posting $3.14 million in receipts for the March 2026 quarter; a 154% jump from the same period last year and a 9% increase on the December 2025 quarter. This milestone underscores the company’s rapid scaling across its diversified healthcare operations, with a consolidated revenue tally of $3.29 million for the quarter, translating into an annualised run-rate of approximately $13.2 million.

This surge is the latest in a series of strong financial performances, following the company’s recent 96% year-on-year growth in December quarter receipts, which marked its reinstatement to the ASX and a clear turnaround from prior challenges.

Contract Manufacturing Drives Momentum

Epsilon Pharma, the company’s contract development and manufacturing organisation (CDMO) based in Southport, has been a key growth engine. It delivered a 149% year-on-year increase in revenue for the quarter, fueled by expanding manufacturing activities and a growing pipeline of domestic and international contracts. The division’s dual GMP licensures, including European certification, have opened doors to new markets, cementing its position as a trusted partner in natural medicines and active pharmaceutical ingredient manufacturing.

This momentum builds on the earlier signing of a significant manufacturing agreement with Puro NZ to supply medicinal cannabis products to the UK and Europe, a deal that underscores Epsilon’s expanding international footprint and was detailed in the company’s AU$6M contract with Puro New Zealand earlier this year.

Pharmacy and Clinics Expansion Bolster Integrated Model

Complementing manufacturing, Epsilon’s Clinics division maintained steady patient volumes and recurring revenues, leveraging telehealth services to enhance accessibility and patient outcomes. The division’s integrated approach is designed to create synergies across the group’s healthcare ecosystem, supporting long-term growth.

Meanwhile, Epsilon Pharmacy, established just a year ago, has quickly scaled to an annualised revenue run-rate of $2.3 million. The company is poised to open its first full-line community pharmacy in Newtown, Sydney, in Q2 2026. This physical expansion, paired with a planned digital patient portal launch, aims to deepen patient engagement and broaden service offerings. The pharmacy’s rapid growth trajectory follows the company’s strategic push to diversify and vertically integrate its healthcare services, a theme echoed in its 2025 turnaround with pharmacy launch that saw losses narrow sharply.

Disciplined Capital Management Supports Growth Ambitions

Epsilon has bolstered its liquidity position, ending the quarter with $503,000 in cash and access to $2 million in unused financing facilities. The company’s capital deployment has focused on securing critical inventory to support its manufacturing cadence and scaling operations. Notably, labour and administration costs have been managed down, enhancing operating leverage as revenues rise.

Managing Director Peter Giannopoulos emphasised the company’s strategic focus on disciplined capital allocation and capability enhancement, positioning Epsilon for sustained expansion and shareholder value creation. The company’s funding structure includes secured loans at competitive rates, with maturity dates extending into 2027 and beyond, providing financial stability to back its growth plans.

Outlook Anchored in Integrated Healthcare Platform

Looking ahead, Epsilon aims to accelerate growth across manufacturing, clinics, and pharmacy, leveraging its vertically integrated platform to capture emerging opportunities domestically and internationally. The upcoming pharmacy launch and continued expansion of contract manufacturing contracts are key near-term catalysts. The company’s strategy to build a sovereign healthcare ecosystem, combining GMP manufacturing, patient-centric clinics, and pharmacy services, sets a foundation for scalable growth and margin expansion.

While the company’s results highlight strong topline momentum, profitability metrics remain undisclosed, leaving some uncertainty around operating margins and cash flow sustainability. Additionally, the pace and scale of international expansion will be critical to watch as Epsilon pursues global market penetration.